In our previous study, we demonstrated that tumor-derived IL-6 positively correlated with MDSC infiltration in situ in human primary breast cancer tissues, which correlated with more aggressive tumor phenotypes and worse clinical outcomes (9). The gene discussed is IL6; the disease is breast carcinoma.